FDA approves first oral treatment for dermatomyositis
The FDA has cleared the first pill developed specifically to treat adults with dermatomyositis, offering improved muscle and skin outcomes in trials while carrying notable risks.
The U.S. Food and Drug Administration has approved the first oral medicine designed to treat adults with dermatomyositis, a rare and debilitating autoimmune condition that attacks the muscles and skin.